Diagnostics and treatment delay in primary central nervous system lymphoma: What the neurosurgeon should know - Takeaways - MDSpire

Diagnostics and treatment delay in primary central nervous system lymphoma: What the neurosurgeon should know

  • By

  • M. C. Hasner

  • M. P. van Opijnen

  • M. van der Meulen

  • R. M. Verdijk

  • S. L. N. Maas

  • L. C. J. te Boome

  • M. L. D. Broekman

  • June 11, 2024

  • 0 min

Share

  • 1

    Primary central nervous system lymphomas (PCNSL) are rare, comprising less than 1% of lymphomas and 4% of brain tumors.

  • 2

    PCNSL is most commonly associated with immunodeficiency and presents with symptoms like cognitive changes, focal deficits, and headaches.

  • 3

    High-dose methotrexate is the cornerstone of PCNSL treatment, but there is no standardized international treatment protocol.

  • 4

    The gold standard for diagnosing PCNSL is histopathological analysis after a stereotactic biopsy, with a diagnostic yield over 91%.

  • 5

    Prognosis for PCNSL varies significantly with age, with a 5-year overall survival rate of 35% for the total population and only 6% for those over 70.

Original Source(s)

Diagnostics and treatment delay in primary central nervous system lymphoma: What the neurosurgeon should know

  • by M. C. Hasner, M. P. van Opijnen, M. van der Meulen, R. M. Verdijk, S. L. N. Maas, L. C. J. te Boome, M. L. D. Broekman

  • June 11, 2024

Related Content

Temporal Changes in Brain Metastasis Resection Sites Following Adjuvant Gamma Knife Radiosurgery

Evaluation of intraoperative color Doppler ultrasonography in the surgical evacuation of acute intracranial hematoma: a single-center study from Botswana

Stereotactic Intracranial Biopsy Outcomes: Insights from a 15-Year Institutional Review